Diabetes (type 1 and type 2) in children and young people: diagnosis and management

Evidence reviews

Evidence for the 2023 recommendations can be found in the evidence review on glucose-lowering agents for managing blood glucose levels in children and young people with type 2 diabetes.

Evidence for the 2022 recommendations can be found in the evidence reviews on continuous glucose monitoring in children and young people with type 1 diabetes and periodontal treatment to improve diabetic control in children and young people with type 1 or type 2 diabetes.

Evidence for the 2020 recommendations can be found in the evidence review on fluid therapy for the management of diabetic ketoacidosis.

In 2018 we reviewed the evidence for SGLT2 inhibitors and GLP-1 mimetics, and made no new recommendations. See the evidence review on SGLT2 inhibitors and GLP-1 mimetics for more information.

Evidence for the 2015 recommendations can be found in the 2015 full guideline on type 1 and type 2 diabetes in children and young people, and supporting appendices:

• Full guideline
• Appendices A-N
• Appendix I